David is head of the corporate practice of our Belgium office. With over 18 years of extensive industry experience, David specialises in every aspect of corporate transactional work, such as public and private M&A, venture capital transactions, general corporate lending, public offerings and general company law. A significant proportion of David’s work focuses on the life sciences and biotech sectors.
Recent work highlights include advising TiGenix on its Nasdaq IPO and public takeover by Takeda, advising the group onepoint on its public takeover bid on Vision IT Group and a series of financing and capital market transactions for leading Belgian biotech companies.
He obtained his law degree from the KU Leuven (2001) and an LL.M at King’s College London (2003).
Hadrien is a Partner in the Brussels corporate department. He advises on public and private M&A and acts for clients on all kinds of transactional matters.
Hadrien is an experienced Corporate lawyer who specialises in mergers and acquisitions (M&A), venture capital, public offerings, corporate reorganisations, corporate and security law, and corporate finance. His main focus areas are the Life Sciences, Digital Business and Transportation & Automotive sectors. He regularly advises on M&A transactions, joint ventures and investment schemes. Hadrien assists in setting-up, financing, reorganising, acquiring, or liquidating business ventures in Belgium. He also acts as a litigator in these matters and in market abuse disputes.
Hadrien became a partner at Osborne Clarke in 2019. Hadrien has a range of specialized experience, having worked as an Associate in Hong Kong in 2015 and having carried out a secondment at a leading global provider of specialised transportation and logistics in 2014.
MEET OSBORNE CLARKE @ #KFG2019
Osborne Clarke will present a workshop in the AM workshop session, presented by David Haex and Hadrien Chef.
"Digital transformation in the LS&H sector: trends and legal challenges"
The workshop will highlight current market trends in the digital transformation of the Life Sciences sector. We will also focus on the legal implications of introducing new technologies and business processes. We will look specifically at the legal challenges around collecting, exchanging and securing data as part of transformation projects. We will further illustrate findings on the basis of selected case studies.